US 12,102,713 B2
Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease
Noriaki Nagai, Higashiosaka (JP); Shunsuke Sakurai, Kawasaki (JP); and Eiji Harata, Kawasaki (JP)
Assigned to NOF CORPORATION, Tokyo (JP); and Kinki University, Higashiosaka (JP)
Filed by NOF CORPORATION, Tokyo (JP); and KINKI UNIVERSITY, Higashiosaka (JP)
Filed on Sep. 6, 2022, as Appl. No. 17/903,597.
Claims priority of application No. 2021-145583 (JP), filed on Sep. 7, 2021; and application No. 2022-141056 (JP), filed on Sep. 5, 2022.
Prior Publication US 2023/0355512 A1, Nov. 9, 2023
Int. Cl. A61K 31/728 (2006.01); A61K 9/00 (2006.01); A61K 31/4704 (2006.01); A61K 31/7084 (2006.01); A61P 27/04 (2006.01)
CPC A61K 9/0048 (2013.01) [A61K 31/4704 (2013.01); A61K 31/7084 (2013.01); A61K 31/728 (2013.01); A61P 27/04 (2018.01)] 13 Claims
 
1. A method of retaining a drug on an ocular surface, comprising administering, to a mammal, an eye drop for treating an ocular disease, and a composition containing 0.001 w/v % to 1.0 w/v % of a copolymer (P) which consists of constituent units represented by the following general formulae (1a) to (1c), has a weight-average molecular weight of from 5,000 to 2,000,000, and has a molar ratio among the constituent units (1a):(1b):(1c) of 100:from 10 to 400:from 2 to 50:

OG Complex Work Unit Chemistry
in the general formula (1a), R1 represents a hydrogen atom or a methyl group;

OG Complex Work Unit Chemistry
in the general formula (1b), R2 represents a hydrogen atom or a methyl group, and R3 and R4 each independently represent a hydrogen atom, a methyl group, or an ethyl group, or represent a morpholino group by being bonded to each other, and

OG Complex Work Unit Chemistry
in the general formula (1c), R5 represents a hydrogen atom or a methyl group, and R6 represents a hydrocarbon group having 12 to 24 carbon atoms.